2025
A Review of Relapse in Opioid Use Disorder
Draghmeh K, Gold M, Fuehrlein B. A Review of Relapse in Opioid Use Disorder. Current Addiction Reports 2025, 12: 58. DOI: 10.1007/s40429-025-00672-5.Peer-Reviewed Original ResearchUse disorderEnhance treatment retentionMindfulness-based therapyStress system dysregulationRelapse vulnerabilityOpioid use disorderNeurobiological mechanismsDopamine deficitMedication-assisted treatmentContingency managementTreatment retentionPsychosocial interventionsMechanisms of relapseReduce relapseBehavioral componentsReviewOpioid use disorderSignificant public health challengeSystem dysregulationPublic health challengeRelapse rateAt-risk populationsSocietal burdenEmergency therapyAt-riskRelapseEfficacy of Total‐Body Irradiation‐based Intensified Myeloablative Regimens for Acute Leukemia—An International Collaborative Study
Arai Y, Brazauskas R, He N, Al‐Homsi A, Chhabra S, Battiwalla M, Yanada M, Steinberg A, Perez M, Hong S, Kanda J, Bashey A, Frangoul H, Badawy S, Verdonck L, Lazarus H, Yared J, Hashem H, Sharma A, Aljurf M, Dias A, Abid M, Wirk B, Freytes C, Zeidan A, Gergis U, Beitinjaneh A, Askar M, Pu J, Lehmann L, Rangarajan H, Wood W, Hashmi S, Yano S, Kako S, Ozawa Y, Doki N, Kanda Y, Fukuda T, Katayama Y, Ichinohe T, Tanaka J, Teshima T, Okamoto S, Atsuta Y, Saber W. Efficacy of Total‐Body Irradiation‐based Intensified Myeloablative Regimens for Acute Leukemia—An International Collaborative Study. EJHaem 2025, 6: e70061. PMID: 40438703, PMCID: PMC12118588, DOI: 10.1002/jha2.70061.Peer-Reviewed Original ResearchTreatment-related mortalityAcute lymphoblastic leukemiaAcute myeloid leukemiaHematopoietic stem cell transplantationOverall survivalConditioning regimensAllogeneic hematopoietic stem cell transplantationMyeloablative allogeneic hematopoietic stem cell transplantationConditioning regimen of cyclophosphamideMyeloablative conditioning regimensRegimen of cyclophosphamideTotal body irradiationStem cell transplantationRisk of relapseMyeloablative regimensCell transplantationAcute leukemiaLymphoblastic leukemiaMyeloid leukemiaAdult patientsCY/TBIClinical trial registrationRegimensInternational collaborative studyRelapseClinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study
Pusztai L, Sondak V, Aguiar-Ibáñez R, Cappuzzo F, Chouaid C, Elder C, Hirasawa Y, Ishida M, Jones R, Lee S, Mizuno R, Nagata M, Okonji D, Parente P, Shah B, Sun A, Ferreira D, Spiteri C, Lauer A, Kaliasethi A, Kao C, Kothari S, McKendrick J. Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study. Journal For ImmunoTherapy Of Cancer 2025, 13: e011184. PMID: 40425232, PMCID: PMC12107590, DOI: 10.1136/jitc-2024-011184.Peer-Reviewed Original ResearchConceptsAnti-PD-(L)1 treatmentAnti-PD-(L)1Anti-PD-(L)1 therapyEarly-stage cancerAnti-PD-(L)1 agentsRetreatment of patientsAnti-programmed deathTreating early-stage cancersAdjuvant settingMetastatic settingNeoadjuvant settingRetreatment patientsClinical expertsAdjuvant treatmentEarly-stage treatmentRetreatment decisionsClinical factorsRepeated treatmentTherapyCancer typesCancerPatient responseClinical practicePatientsRelapseComparative effectiveness of long-acting injectable versus oral antipsychotic medication after a first episode of psychosis
Szmulewicz A, Martínez-Alés G, Logan R, Joober R, Ferrara M, Kelly C, Fredrikson D, Thorpe L, Conderino S, Díaz-Caneja C, Srihari V, Yatham L, Sarpal D, Shinn A, Arango C, Shah J, Öngür D, Hernán M. Comparative effectiveness of long-acting injectable versus oral antipsychotic medication after a first episode of psychosis. Nature Mental Health 2025, 3: 421-428. DOI: 10.1038/s44220-025-00407-5.Peer-Reviewed Original ResearchEpisode of psychosisPsychotic relapseLong-actingTarget trialsRisk of psychotic relapseLong-acting antipsychoticsOral antipsychotic medicationEffects of long-actingLAI therapyAntipsychotic therapyAntipsychotic medicationSchizophrenia trialsTherapy initiationRisk of relapseOral therapyPsychosisRisk differenceFEPObservational cohort of peopleHospitalization riskCohort of peopleNetwork meta-analysesNo risk reductionNon-adherenceRelapseA niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies
Mosialou I, Ali A, Labella R, Bisikirska B, Cuesta-Dominguez A, Vgenopoulou P, Reyes I, Rao S, Wang A, Luo N, Galan-Diez M, Zhao J, Chernak B, Bewersdorf J, Fukasawa K, Su J, Higa J, Adams R, Corper A, Pampou S, Woods C, Fan X, Shah R, Feldstein J, Liu N, Liang C, Heiblig M, Kornblau S, Garcia-Manero G, Berman E, Jurcic J, Rabadan R, Raza A, Kousteni S. A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies. Cancer Cell 2025, 43: 1007-1024.e13. PMID: 40154481, PMCID: PMC12151774, DOI: 10.1016/j.ccell.2025.03.007.Peer-Reviewed Original ResearchConceptsStandard of careAcute myeloid leukemiaAll-trans-retinoic acidMyelodysplastic syndromeMyeloid malignanciesLeukemic micePatients treated with all-trans-retinoic acidMDS/AML cellsResponse to therapyResistance to standardResponse to ATRAMyeloid leukemiaTargeted therapyMyeloid cancersAssociated with activationMutation profilesTherapeutic approachesImproved efficacyDisease outcomeMiceRelapseMalignancyTherapyPatientsOsteoblastic cellsGambling disorder and problematic pornography use: Does co-occurrence influence treatment outcome?
Mestre-Bach G, Potenza M, Granero R, Håkansson A, Gómez-Peña M, Perales I, Vicó À, Uríszar J, Fernández-Aranda F, Sánchez I, Jiménez-Murcia S. Gambling disorder and problematic pornography use: Does co-occurrence influence treatment outcome? Journal Of Behavioral Addictions 2025, 14: 465-479. PMID: 40116860, PMCID: PMC11974433, DOI: 10.1556/2006.2025.00023.Peer-Reviewed Original ResearchConceptsCognitive-behavioral therapyGambling disorderPornography useEmotion regulationGD severityTreatment outcomesCognitive-behavioral therapy approachCognitive-behavioral therapy sessionsTreatment outcomes of individualsCo-occurrence of GDCo-occurrenceMental health concernsImprove treatment adherenceBehavioral addictionsTreatment dropoutOutcomes of individualsWeekly sessionsTreatment adherencePsychopathologyGamblingSessionsDisordersAssociated with higher likelihoodRelapseImpulseChimerism testing in myeloid malignancies: techniques, considerations, and connections to post-transplant outcomes
Puzo C, Siddon A. Chimerism testing in myeloid malignancies: techniques, considerations, and connections to post-transplant outcomes. Pathology 2025, 57: 267-275. PMID: 39934013, DOI: 10.1016/j.pathol.2024.12.632.Peer-Reviewed Original ResearchLineage specific chimerismChimerism testingMyeloid malignanciesCell burdenHematopoietic cellsPost allogeneic stem cell transplantationHost hematopoietic cellsMalignant cell burdenLeukemic cell burdenStem cell transplantationRisk of relapseRecipient hematopoietic cellsPost-transplant outcomesCell transplantationRelapse detectionRecipient chimerismTherapy decisionsRelapsePercentage of donorsChimerismHigh riskConcurrent useChimerism percentageEarly identificationMalignancyTumefactive and longitudinally extensive myelitis: A rare presentation of multiple sclerosis?
Morehead A, Flanagan E, Solomon A. Tumefactive and longitudinally extensive myelitis: A rare presentation of multiple sclerosis? Neuroimmunology Reports 2025, 7: 100257. DOI: 10.1016/j.nerep.2025.100257.Peer-Reviewed Original ResearchSpinal cord demyelinationMultiple sclerosisCervical spinal cord lesionLongitudinally extensive myelitisPresentation of multiple sclerosisTumefactive demyelinating lesionsRare presentation of multiple sclerosisTherapeutic decision-makingRelapsing-remitting MSSpinal cord lesionsRare presentationClinical courseCord lesionsPrognostic challengesLongitudinal followDemyelinationLesionsSclerosisUnmet needsRelapseMyelitisPatientsFollow
2024
Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort
Laakso S, Oh J, Raufdeen F, Jones A, Reiskanen H, Feb K, Levit E, Solomon A. Trigeminal neuralgia within the disease course of MS: Diagnostic and therapeutic implications from a multicenter cohort. Multiple Sclerosis Journal 2024, 31: 607-611. PMID: 39727322, DOI: 10.1177/13524585241309257.Peer-Reviewed Original ResearchTrigeminal neuralgiaClinical relapseMultiple sclerosisActive diseaseEvidence of active diseaseDisease course of MSAssociated with multiple sclerosisCourse of MSDemyelination symptomsMulticenter cohortDisease courseTherapeutic decisionsTherapeutic implicationsMS diagnosisNeuralgiaRelapseDiseaseOnsetSclerosisPsychological, Behavioral, and Pharmacological Treatments for Binge Eating Disorder
Chao A, Grilo C. Psychological, Behavioral, and Pharmacological Treatments for Binge Eating Disorder. 2024, 378-390. DOI: 10.1093/oso/9780190671051.003.0043.Peer-Reviewed Original ResearchBinge eating disorderAddiction perspectiveAddiction modelTreatment of binge eating disorderFeatures of binge eating disorderBinge eating disorder treatmentPharmacological treatmentNon-substance addictionBrain-based diseaseFood addictionEating disordersAddiction conceptAddictionTreatment approachesDisordersHarm reductionClinical observationsAbstinenceBingeSubstancesBehaviorRelapseTreatmentSuggestionsHarmUltra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
Li X, Liu T, Bacchiocchi A, Li M, Cheng W, Wittkop T, Mendez F, Wang Y, Tang P, Yao Q, Bosenberg M, Sznol M, Yan Q, Faham M, Weng L, Halaban R, Jin H, Hu Z. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. EMBO Molecular Medicine 2024, 16: 2188-2209. PMID: 39164471, PMCID: PMC11393307, DOI: 10.1038/s44321-024-00115-0.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNAWhole-genome sequencingCell-free DNAGenome sequenceDetection of molecular residual diseaseCirculating tumor DNA detectionResidual disease detectionConsistent with clinical outcomesVariant allele frequencyResidual diseaseMelanoma patientsMonitoring immunotherapyTumor DNAEsophageal cancerClinical outcomesColorectal cancerWGS technologiesAllele frequenciesCancerDNAAnalytical sensitivitySequenceImmunotherapyRelapseStress and substance use disorders: risk, relapse, and treatment outcomes
Sinha R. Stress and substance use disorders: risk, relapse, and treatment outcomes. Journal Of Clinical Investigation 2024, 134: e172883. PMID: 39145454, PMCID: PMC11324296, DOI: 10.1172/jci172883.Peer-Reviewed Original ResearchConceptsSubstance use disordersDrug-related environmentPathophysiology of addictionAdaptive stress responseSUD treatment outcomesAssociated with substance misuseTreatment outcomesStress-related alterationsDrug motivationIncreased cravingNeurobiological disruptionsMaladaptive copingRepeated stressorsTreatment implicationsSubstance misuseStress pathophysiologyStress responseDrug intakeDrug withdrawalRelapse riskDrug misuseIntervention developmentDisordersCravingRelapseBuprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
Balter D, Puglisi L, Dziura J, Fiellin D, Howell B. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial. Journal Of Substance Use And Addiction Treatment 2024, 164: 209438. PMID: 38857827, PMCID: PMC11300157, DOI: 10.1016/j.josat.2024.209438.Peer-Reviewed Original ResearchXR-NTXBuprenorphine-naloxoneOpioid use disorderCriminal legal involvementUse disorderHazard of overdoseLifetime incarcerationLegal involvementOpioid use disorder treatment outcomesPer-protocol analysisExtended-release naltrexoneMOUD effectivenessTreatment outcomesEffects of medicationHazard of relapseSecondary analysisIntention-to-treat analysisIntention-to-treatRandomized controlled trialsEffects of MOUDRelapseControlled trialsDisordersOpioidPotential effect modifiersBig Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives.
Wang X, Chiang A. Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives. American Society Of Clinical Oncology Educational Book 2024, 44: e432520. PMID: 38830134, DOI: 10.1200/edbk_432520.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerLung cancerSystemic therapyHigh-grade neuroendocrine carcinomaAssociated with tobacco useIntracranial radiotherapySCLC treatmentChemosensitive diseaseNeuroendocrine carcinomaTargeted therapyPatientsCancerTherapyTobacco usePsychosocial burdenDiseasePatient perspectiveRadiotherapyImmunotherapyCarcinomaRelapseThoracicLungClinicNicotine Use Disorder
Khan A, Tampi R, Tampi D. Nicotine Use Disorder. 2024, 227-239. DOI: 10.1007/978-3-031-55711-8_16.Peer-Reviewed Original ResearchOlder adultsNicotine use disorderCombination of pharmacotherapyCessation interventionsNicotine replacement therapyRelapse preventionUse disorderBehavioral interventionsRelapsing conditionQuit smokingPopulation of older adultsSmoking cessationFood and Drug AdministrationNicotineReplacement therapyAdultsDrug AdministrationEffective cessation interventionsTobacco useInterventionRelapseBupropionVareniclinePharmacotherapyCessationNormal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain
Prior D, Sowa A, Pashankar F. Normal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain. Journal Of Pediatric Hematology/Oncology 2024, 46: e195-e198. PMID: 38277626, DOI: 10.1097/mph.0000000000002820.Peer-Reviewed Original ResearchConceptsDiamond-Blackfan anemiaDiamond-BlackfanDiagnosis of Diamond-Blackfan anemiaInherited bone marrow failure syndromeBone marrow failure syndromesMarrow failure syndromesDiagnostically challenging casesFailure syndromeAtypical manifestationsSpontaneous remissionRare caseErythroid precursorsChallenging casesGenetic etiologyPhenotypic manifestationsAnemiaPatientsRemissionRelapseHypoplasiaSyndromeEtiologyDiagnosis
2023
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
Krystal J, Kaye A, Jefferson S, Girgenti M, Wilkinson S, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2305772120. PMID: 38011560, PMCID: PMC10710048, DOI: 10.1073/pnas.2305772120.Peer-Reviewed Original ResearchMOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity
Yandamuri S, Filipek B, Obaid A, Lele N, Thurman J, Makhani N, Nowak R, Guo Y, Lucchinetti C, Flanagan E, Longbrake E, O’Connor K. MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity. JCI Insight 2023, 8: e165373. PMID: 37097758, PMCID: PMC10393237, DOI: 10.1172/jci.insight.165373.Peer-Reviewed Original ResearchConceptsMyelin oligodendrocyte glycoprotein antibody-associated diseaseAntibody-dependent cellular phagocytosisAntibody-dependent cellular cytotoxicityComplement-dependent cytotoxicityMOG autoantibodiesPatient seraCellular cytotoxicityEffector functionsComplement activityAntibody-associated diseaseMultiple mechanismsNK cellsPatient autoantibodiesCytotoxic capacityLesion histologyCellular phagocytosisFuture relapseIgG subclassesCerebrospinal fluidAutoantibodiesCNS conditionsMOGSerumRelapseCytotoxicityPredictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Singh S, Jangi S. Predictors and Etiologies of Clinical Relapse Among Patients With Ulcerative Colitis in Deep Remission. Journal Of Clinical Gastroenterology 2023, 58: 195-199. PMID: 36753459, PMCID: PMC10406966, DOI: 10.1097/mcg.0000000000001834.Peer-Reviewed Original ResearchConceptsEtiology of relapseRisk of relapseCumulative risk of relapseRisk of clinical relapseDeep remissionDiscontinuation of therapyClinical relapseUlcerative colitisNormalization of C-reactive proteinCumulative riskRetrospective cohort studyC-reactive proteinTufts Medical CenterEndoscopic remissionHistological remissionRelapse riskIdentified etiologyRemissionRelapseCohort studyPatientsHistological changesMedical recordsColitisElectronic medical recordsAn overview of novel therapies in advanced clinical testing for acute myeloid leukemia
Venugopal S, Xie Z, Zeidan A. An overview of novel therapies in advanced clinical testing for acute myeloid leukemia. Expert Review Of Hematology 2023, 16: 109-119. PMID: 36718500, DOI: 10.1080/17474086.2023.2174521.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAML therapyMolecular pathogenesisApproval of midostaurinPathophysiology of AMLMeasurable residual diseaseAdvanced clinical testingClinical trial developmentAcute myeloid leukemiaCell surface antigensDevelopment of agentsDisease relapseImmune environmentAML treatmentResidual diseaseTherapeutic armamentariumMyeloid leukemiaNovel therapiesSurface antigenClinical testingTrial developmentTherapyAMLEscape mechanismsGene mutationsRelapse
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply